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Objectives. This study investigated the hemostatic status of the 
right and left atria in patients with mitral stenosis. 
Background. Systemic thromboembolism is a serious major 
complication in patients with mitral stenosis. However, the patho- 
genesis of thromboembolism in mitral stenosis is not fully under- 
stood. 
Methods. We determined the plasma levels of biochemical 
markers for platelet activity (platelet factor 4 and beta- 
thrombogiobulin) and status of thrombin generation (fibrinopep- 
tide A and thrombin-antithrombin III complex) and ftbrinolysis 
(D-dimer and plasmin-alpha2-plasmin i hibitor complex) in 
specimens of blood obtained from the peripheral vein and right 
and left atria of 12 consecutive patients with mitral stenosis who 
were undergoing percutaneous mitral valvuloplasty. 
Results. Plasma levels of platelet factor 4, beta-thromboglobulin, 
D-dimer and plasmin-alpha2-plasmin hibitor complex in the pa- 
tients did not differ significantly between the right and left atria, 
whereas levels of fibrinopeptide A and thrombin--antithrombin III
complex in the left atrium were significantly higher than those in the 
right atrium (fibrinopeptide A in the left and right atria 1935 - 4.64 
and 631 -+ 0.75 ng/ml [mean ± SE], respectively, p < 0.02; 
thrombin-antithrombin HI complex in the left and right atria 
11.45 ± 2.29 and 3.98 ± 0.60 ng/ml, respectively, p < 0.01). Levels of 
fibrinopeptide A and thrombin-antithrombin IlI complex in the left 
atrium did not correlate with mean transmitral gradient, dimension 
of the left atrium or reciprocal of the mitral valve area. Peripheral 
blood plasma levels of von Willebrand factor antigen were signifi- 
cantly higher in the patients than in an age-matched control group of 
normal subjects (168 ± 25% and 99 __ 7%, respectively, p < 0.05) but 
showed no difference in the peripheral blood and right and left atria 
of the patients. 
Conclusions. The coagulation system is activated in the left 
atrium of patients with mitral stenosis even during anticoagula- 
tion. 
(J Am Coll Cardiol 1995;25:107-12) 
Systemic thromboembolism is a serious complication in pa- 
tients with valvular heart disease, and its incidence is highest in 
those with mitral stenosis (1-7). The incidence of embolism in 
large groups of such patients is -4%/year (8). The Framing- 
ham Study (9) reported an 18-fold increase in the incidence of 
stroke in patients who had mitral stenosis and atrial fibrillation 
compared with matched control subjects. Thus, the prophylac- 
tic administration f anticoagulant agents appears to be indi- 
cated in selected patients with mitral stenosis, especially those 
with atrial fibrillation (10). However, the efficacy of platelet 
antiaggregant agents, such as aspirin, has not been convinc- 
ingly established. 
Sensitive new biochemical markers for assessing platelet 
activity and the status of thrombin generation and fibrinolysis 
have made it possible to evaluate such activities in patients 
with valvular heart disease, ischemic heart disease, deep vein 
thrombosis and pulmonary embolism (11-20). It has been 
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reported that plasma levels of D-dimer and thrombin- 
antithrombin III complex (12) and yon Willebrand factor 
antigen (15) are significantly elevated in patients with mitral 
stenosis. However, these studies evaluated hemostatic status 
only at the peripheral level and evaluated blood obtained from 
the peripheral vein. In the present study, we investigated 
plasma levels of biochemical markers for platelet activity and 
the status of thrombin generation and fibrinolysis in the 
peripheral vein and right and left atria of 12 consecutive 
patients with rheumatic mitral stenosis who were undergoing 
percutaneous mitral valvuloplasty. We believe that this is the 
first report o discuss the hemostatic status of the atria in such 
patients. 
Methods  
Clinical characteristics. Between March 1992 and March 
1993, 12 patients (2 men, 10 women; mean [_SE] age 53 ± 2 
years, range 39 to 68) with severe rheumatic mitral stenosis 
underwent percutaneous mitral valvuloplasty by the antegrade 
transseptal pproach using an Inoue balloon (21). Their clin- 
ical characteristics are summarized inTable 1. Eleven patients 
had chronic atrial fibrillation, and one had sinus rhythm before 
valvuloplasty. M1 11 patients with atrial fibrillation had re- 
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Table 1. Clinical Characteristics of 12 Patients Who Underwent 
Percutaneous Mitral Valvuloplasty 
Gender (M/F) 
Age (yr) 
History of rheumatic fever 
Previous urgical commissurotomy 
Previous PMV 








Mitral calcification (fluoroscopy) 
Mean left atrial diameter (ram) 





Mean transmitral gradient (ram Hg) 
















13.6 _+ 1.6 
0.81 _+ 0.07 
Data presented are mean value _+ SE or number of patients. F - female; 
INR = international normalized ratio; M = male; NYHA = New York Heart 
Association; PMV - percutaneous mitral valvuloplasty. 
ceived warfarin therapy for at least 3 months (international 
normalized ratio 2.0 to 4.0, mean [_+SE] 2.7 _+ 0.1) but no 
antiplatelet drugs or hemorrheologically active agents, such as 
analgesic agents and estrogen-containing drugs. According to 
the practice of our cardiac atheterization laboratory, warfarin 
administration was stopped on the day of valvuloplasty. Nine 
patients were in New York Heart Association functional class 
II and three in class III. One patient had previously undergone 
commissurotomy, and one had a previous percutaneous mitral 
valvuloplasty. Criteria for exclusion from valvuloplasty were 
significant rnitral regurgitation, aortic stenosis, aortic regurgi- 
tation, history of systemic embolism, left atrial clot (as detected 
by two-dimensional transesophageal chocardiography with a 
biplane probe), diabetes mellitus and renal or hepatic insuffi- 
ciency. An age-matched control group of 15 normal volunteers 
(3 men, 12 women; mean age 53 _+ 2 years, range 35 to 66) 
received no medications. The study was approved by our 
institututional human investigations committee, and written 
informed consent was obtained from all patients and volun- 
teers before the study. 
All patients underwent M-mode, two-dimensional and 
Doppler echocardiography on the day before valvuloplasty. 
Mean (_+SE) left atrial diameter determined by M-mode 
echocardiography (22) was 59 _+ 2 mm (Table 1). Yransesoph- 
ageal echocardiography performed in all patients detected no 
intracardiac thrombus. Morphologic haracteristics of the mi- 
tral valve and subvalvular structures were classified using an 
echocardiographic s oring system (23). 
Cardiac catheterization and valvuloplasty. Right and left 
heart studies, including measurements of cardiac output, bi- 
plane left ventriculography and right atriography, and coronary 
angiography were performed by the percutaneous technique 
from the left groin immediately before percutaneous mitral 
valvuloplasty. This procedure was performed with an Inoue 
single-balloon catheter (17). In brief, the balloon catheter was 
inserted into the left ventricle transseptally according to the 
Brockenbrough technique. After its distal half was inflated at 
the left ventricle, the balloon was pulled back to the mitral 
orifice. It was then fully inflated until its indentation had 
disappeared. It was then pulled back to the left atrium and 
deflated. The diameter of the inflated balloon was 24 mm in 
five patients, 26 mm in six patients and 28 mm in one patient. 
These manipulations were performed under fluoroscopy with 
the same predetermined projections as those used in left 
ventriculography. Effective areas of balloon dilation were 
determined by geometric analysis and normalized for body 
surface area, as described previously (24). The severity of 
mitral regurgitation was assessed according to the method of 
Sellers et al. (25). Pressures in the left atrium and left ventricle 
were simultaneously recorded to determine the mean transmi- 
tral gradient (13.6 _+ 1.6 mm Hg, mean _+ SE) before valvulo- 
plasty (Table 1). Cardiac output was determined by thermodi- 
lution in 11 patients and by the direct Fick method in one with 
moderate tricuspid regurgitation. Mitral valve area calculated 
by the Gorlin formula (26) was 0.81 + 0.07 cm 2 (mean _+ SE) 
before valvuloplasty. 
Blood sampling. Samples of the peripheral venous blood 
were obtained for measurement of molecular markers at 9 AM 
before percutaneous mitral valvuloplasty o exclude the possi- 
ble influence of circadian variations (27-29). Immediately 
before the administration f heparin and inflation of balloon 
during valvuloplasty, blood samples were obtained from the 
left and right atria through athermodilution catheter (7F) and 
an Inoue balloon catheter (12F), respectively. A trained phy- 
sician carried out blood sampling using the two-syringe tech- 
nique. A preliminary study showed no difference in the levels 
of biochemical markers in samples obtained from the same 
sites through the two types of catheters, and drawing blood 
samples from these catheters did not cause an artificial in- 
crease in the levels of biochemical markers. Nine parts of 
whole blood were mixed with one part of 3.8% sodium citrate 
solution for assay of thrombin-antithrombin III complex, 
plasmin-alphae-plasmin inhibitor complex and von Willebrand 
factor antigen. Four parts of whole blood were gently mixed 
with one part of a solution containing sodium citrate, theo- 
phylline, adenosine and dipyridamole for assay of platelet 
factor 4 and beta-thromboglobulin (30). A volume of 1.6 ml of 
whole blood was drawn into a plastic tube containing 200 U of 
heparin and 4,000 klU of aprotinin for assay of fibrinopeptide 
A and D-dimer. Plasma was separated by centrifugation at
2,000 g for 30 min and stored at -80°C until the molecular 
markers were assayed. 
Plasma assays. Enzyme-linked immunosorbent assay 
(ELISA) kits (Diagnostica Stago, Asnibres, France) were used 
for quantitative determination f platelet factor 4 and beta- 
thromboglobulin (31). Levels of fibrinopeptide A, thrombin- 
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Figure 1. Scatterplots showing plasma levels of platelet factor 4 (PF4) 
and beta-thromboglobulin (/3TG) in normal subjects (n = 15) and in 
the peripheral blood and right (RA) and left (LA) atria of patients 
with mitral stenosis (MS) (n = 12). PV = peripheral vein. Data are 
mean value +_ SE. 
antithrombin II I  complex, D-dimer and plasmin-alpha 2- 
plasmin inhibitor complex were also determined with ELISA 
kits (Diagnostica Stago; Behringe Werke, Marburg, Germany; 
Agen Biomedical, Brisbane, Australia; and Teijin, Tokyo, 
Japan, respectively) (32-35). Concentrations of von Wille- 
brand factor antigen were determined by ELISA (Diagnostica 
Stago) (36), with values expressed as a percent of that obtained 
in pooled normal plasma. 
Statistical analysis. Data are expressed as mean value _ SE. 
Differences were analyzed by one-way analysis of variance com- 
bined with the Scheff6 test. Simple linear regression analysis was 
used to compare measurements obtained by means of catheter- 
ization or ultrasound as well as the levels of molecular markers for 
platelet activity and status of thrombin generation and fibrinoly- 
sis; p < 0.05 was considered statistically significant. 
Resu l ts  
Platelet activity. Figure 1 and Table 2 show the plasma 
levels of platelet factor 4 and beta-thromboglobulin used to 
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Figure 2. Scatterplots howing plasma levels of fibrinopeptide A
(FPA) and thrombin-antithrombin III complex (TAT) in normal 
subjects (n = 15) and in the peripheral blood and right (RA) and left 
(LA) atria of patients with mitral stenosis (MS) (n = 12). In patients 
with mitral stenosis, peripheral blood plasma fibrinopeptide A levels 
were significantly higher than those in normal subjects, and plasma 
fibrinopeptide A and thrombin-antithrombin III complex levels in the 
left atrium were significantly higher than those in the peripheral blood 
and right atrium. PV = peripheral vein. Data are mean value -+ SE. 
peripheral blood did not differ significantly between patients 
with mitral stenosis and normal subjects. Levels of platelet 
factor 4 in the patients did not differ significantly with respect 
to the peripheral blood and right and left atria. Plasma levels 
of beta-thromboglobulin also did not differ significantly be- 
tween the patients and normal subjects or the peripheral blood 
and right and left atria in the patients. 
Status of thrombin generat ion. Plasma levels of fibrin- 
opeptide A and thrombin-antithrombin III complex used as a 
marker of thrombin activity, are shown in Figures 2 and 3 and 
Table 2. Peripheral blood levels of fibrinopeptide A in the 
patients with mitral stenosis ignificantly exceeded those in the 
normal subjects. Levels of fibrinopeptide A were significantly 
higher in the left atrium than in the peripheral blood or right 
atrium of the patients. Plasma levels of thrombin-antithrombin 
III complex in the peripheral blood did not differ significantly 
Table 2. Biochemical Markers in Normal Subjects and Patients With Mitral Stenosis 
Normal Subjects 
(n = 15) PV RA 
Patients With Mitral Stenosis (n = 12) 
LA 
PF4 (ng/ml) 8.5 -- 1.8 10.8 ± 2.1 20.3 ± 6.1 22.3 ± 5.7 
ffl'G (ng/ml) 34.3 _+ 4.2 39.1 _+ 5.3 48.4 +_ 9.9 55.1 ± 12.2 
FPA (ng/ml) 1.08 _+ 0.19 6.73 _+ 1.53' 6.31 ± 0.75 19.35 ± 4.64I'~: 
TAT (ng/ml) 1.75 _+ 0.19 2.63 -+ 0.44 3.98 _+ 0.60 11.45 ± 2.29§11 
DD (ng/ml) 55.4 -- 5.9 67.9 -- 10.2 63.8 ± 7.6 63.3 ± 7.1 
PIC 0zg/ml) 0.55 ± 0.04 0.69 ± 0.08 0.68 -+ 0.07 0.69 ± 0.07 
vWF:Ag (%) 99 ± 7 168 ± 25¶ 150 ± 23 151 _+ 23 
*p < 0.01, ¶p < 0.05 versus normal subjects, tp < 0.05, §p < 0.01 versus peripheral vein (PV). :~p < 0.02, liP < 0.01 
versus right atrium (RA). Data presented are mean value +_ SE. DD = D-dimer; FPA = fibrinopeptide A; LA = left 
atrium; PF4 = platelet factor 4; PIC = plasmin-alphaz-plasmin inhibitor complex; TAT = thrombin-antithrombin III 
complex; vWF:Ag =von Willebrand factor antigen;/3TG = beta-thromboglobulin. 
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Figure 3. Plasma levels of fibrinopeptide A (FPA) and thrombin- 
antithrombin III complex (TAT) in the right (RA) and left (LA) atria 
of 12 patients with mitral stenosis. Data are mean value _+ SE. 
between patients and normal subjects. However, in the left 
atrium of the patients, these levels significantly exceeded those 
in the peripheral blood or the right atrium. There was a 
significantly positive relation between the plasma levels of 
fibrinopeptide A and thrombin-antithrombin III complex in 
the left atrium of the patients (Fig. 4). 
Fibrinolytie status. Plasma levels of D-dimer and plasmin- 
alpha2-plasmin i hibitor complex, which reflect active fibrinol- 
ysis, are shown in Figure 5 and Table 2. Levels of these 
molecular markers in the peripheral blood did not differ 
significantly between patients and normal subjects. Plasma 
levels of these molecular markers also did not differ signifi- 
cantly in the peripheral blood and right and left atria of the 
patients. 
Levels of von Willebrand factor. Levels of von Willebrand 
factor antigen in the peripheral blood were significantly higher 
in the patients than in the normal subjects but did not differ 
significantly in the peripheral blood and right and left atria of 
the patients (Fig. 6, Table 2). 
Relation between biochemical markers and hemodynamic 
variables. Of the several biochemical markers evaluated in the 
left atrium of patients with mitral stenosis, fibrinopeptide A and 
Figure 4. Relation between plasma levels of fibrinopeptide A (FPA) 
and thrombin-antithrombin Ill complex (TAT) in the left atrium (LA) 
of patients with mitral stenosis. Regression analysis revealed ahighly 
significant relation between the two molecular markers (y - 0.42x + 
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Figure 5. Scatterplots showing plasma levels of D-dimer (DD) and 
plasmin-alpha2-plasmin inhibitor complex (PIC) in normal subjects 
(n = 15) and in the peripheral blood and right (RA) and left (LA) atria 
of patients with mitral stenosis (MS) (n = 12). PV = peripheral vein. 
Data are mean value _+ SE. 
thrombin-antithrombin III complex levels were shown to be 
significantly increased. We then analyzed the correlation between 
the levels of these coagulation markers and hemodynamic vari- 
ables. Plasma levels of fibrinopeptide A and thrombin- 
antithrombin III complex in the left atrium of the patients did not 
correlate well with the diameter of the left atrium, mean trans- 
mitral gradient or reciprocal mitral valve area (Table 3). 
Discuss ion  
Thrombin specifically cleaves fibriuopeptide A from the 
amino termini of the fibrinogen alpha chain and initiates fibrin 
generation (37). Thrombin is very rapidly bound and thereby 
inactivated by its main physiologic inhibitor, antithrombin III, 
producing thrombin-antithrombin III complex. Plasma fibrin- 
opeptide A and thrombin-antithrombin III complex levels 
represent a very sensitive marker for thrombin activity in vivo; 
direct measurement of free thrombin is impossible because of 
Figure 6. Scatterplots showing plasma levels of von Willebrand factor 
antigen (vWF:Ag) in normal subjects (n = 15) and in the peripheral 
blood and right (RA) and left (LA) atria of patients with mitral 
stenosis (MS) (n - 12). Peripheral plasma levels of yon Willebrand 
factor antigen in patients with mitral stenosis ignificantly exceeded 
those determined in normal subjects. PV - peripheral vein. Data are 
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Table 3. Correlation Between Biochemical Markers in 
Left Atrium and Clinical or Hemodynamic Variables in Patients 
With Mitral Stenosis 
FPA (ng/ml) TAT (ng/ml) 
r p r p 
Value Value Value Valuc 
Left atrial diameter (mm) 0.05 0.88 0.11 0,73 
Mean transmitral gradient (mm Hg) 0.42 0.17 0.26 0.41 
l/mitral valve area (cm 2) 0.40 0.20 0.45 0.14 
FPA fibrinopeptide A; TAT - thrombin-antithrombin III complex. 
its very short half-life. In this study, plasma levels of fibrin- 
opeptide A and thrombin-antithrombin III complex in the left 
atrium of patients with mitral stenosis ignificantly exceeded 
those in the peripheral blood or the right atrium, demonstrat- 
ing a state of increased coagulability in the left atrium of these 
patients even during anticoagulation. 
Hemostatic ondition in mitral stenosis. The status of 
thrombin generation and fibrinolysis in the peripheral blood of 
patients with mitral stenosis has been studied by several groups 
(38). Yasaka et al. (12) reported that levels of fibrinopeptide 
A, fibrinopeptide B-beta-I 5-42, D-dimer and antithrombin Ill
in the peripheral blood were significantly higher in patients 
with mitral stenosis than in normal subjects. Jafri et al. (13) 
reported that patients with mitral stenosis who were in sinus 
rhythm showed a significant increase in D-dimer levels in the 
peripheral blood over those in control subjects, uggesting that 
the coagulation system is activated in patients with mitral 
stenosis. In our study, all but one patient had chronic atrial 
fibrillation. Thus, chronic atrial fibrillation may partly contrib- 
ute to the elevated fibrinopeptide A and thrombin-antithrombin 
III complex levels seen in the left atrium. However, levels of 
fibrinopeptide A and thrombin-antithrombin III complex levels 
in the right atrium were not elevated in 11 patients with atrial 
fibrillation compared with levels in the peripheral blood (Fig. 2), 
suggesting that the presence of atrial fibrillation itself does not 
cause an increase in fibrinopeptide A and thrombin-antithrombin 
III complex levels in the left as well as the right atrium. 
A shortened platelet survival time has been documented in
patients with mitral stenosis, uggesting that they have activated 
platelet activity (39). Fukuda and Nakamura (40) reported that 
platelet function was increased in all patients with rheumatic 
valvular disease on the basis of findings of high plasma beta- 
thromboglobulin values. In our study, plasma levels of platelet 
factor 4 and beta-thromboglobulin in the peripheral blood did not 
differ significantly between patients and normal control subjects. 
Levels of platelet factor 4 and beta-thromboglobulin te ded to 
increase in each atrium compared with levels in the peripheral 
blood, but not to a statistically significant extent. We speculate 
that platelet activity is not increased within the cardiac hambers 
of patients with mitral stenosis. However, the possibility that 
platelet function may have been suppressed by warfarin admin- 
istration cannot be ruled out (41). 
In our study, severity of stenosis on the basis of mitral valve 
area was not correlated with levels of fibrinopeptide A and 
thrombin-antithrombin III complex in the left atrium. A 
spontaneous left atrial echo contrast is often observed in 
patients with a history of arterial embolization or left atrial 
thrombi and is associated with conditions that favor stasis of 
blood in the left atrium in mitral stenosis (42,43). Rheologic 
abnormalities inthe left atrium of patients with mitral stenosis 
may contribute to the hypercoagulable status. However, the 
incidence of thromboembolism and the size of the mitral 
orifice do not show a simple correlation (44). In this study, we 
observed spontaneous echo contrast in the left atrium of some 
patients, but there was no relation between its presence and 
levels of fibrinopeptide A and thrombin-antithrombin III 
complex in the left atrium (data not shown). 
The large multimeric glycoprotein, von Willebrand factor, is 
found in endothelial cells, plasma and platelet alpha granules 
and mediates platelet adhesion to the vascular subendothe- 
lium. This protein is essential for the formation of platelet 
thrombi in flow that is characterized by high shear stress (45). 
Penny et al. (15) reported that the von Willebrand factor 
antigen concentration in the peripheral blood was significantly 
higher in patients with mitral stenosis and that this elevation 
was associated with a significant increase in pulmonary vascu- 
lar resistance. These investigators speculated that there was 
increased synthesis of von Willebrand factor in the pulmonary 
circulation in these patients. In the present study, levels of von 
Willebrand factor antigen in the peripheral blood of patients 
with mitral stenosis were significantly higher than those in 
age-matched normal subjects. However, we observed no cor- 
relation between levels of von Willebrand factor antigen and 
pulmonary vascular esistance (r = 0.09, p = 0.54). Patients 
with mitral stenosis howed no significant differences in von 
Willebrand factor antigen levels in peripheral blood and right 
and left atria. Although elevation of von Willebrand factor may 
contribute to the thrombotic tendency seen in patients with 
mitral stenosis, our study could not clarify its site of produc- 
tion. The therapeutic benefit directed at von Willebrand factor 
in these patients also remains to be clarified. 
Adams et al. (46) evaluated 84 patients with mitral stenosis 
followed up for 20 years and found that patients without 
anticoagulation had a higher mortality rate than those with 
anticoagulation. However, there have been no prospective 
randomized trials to evaluate the efficacy of anticoagulation in 
the primary prevention ofsystemic embolism in mitral stenosis. 
Anticoagulation is generally recommended for treating pa- 
tients with mitral stenosis, particularly those with atrial fibril- 
lation, a large left atrium or heart failure or patients with a 
history of systemic embolism (47). Asakura et al. (14) demon- 
strated that patients with mitral stenosis and atrial fibrillation 
showed a highly hypercoagulable status. In vivo activation of 
blood coagulation was more effectively controlled in those 
patients who received warfarin than in those taking aspirin. 
However, the incidence of thromboembolism till can not be 
disregarded with those medications. 
Limitation of the study. We cannot rule out completely the 
effect of puncture of the atrial septum itself on coagulation 
activity in both atria; needle perforation of the septum and 
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catheter dilation of the septal puncture could cause raw edges of 
the septal perforation to be exposed to atrial blood. However, the 
lack of difference in platelet factor 4 and beta-thromboglobulin 
levels between the left and right atria is somewhat indicative that 
the septal wound is not a fatal flaw in this study. 
Conclusions. We believe that our study demonstrates for 
the first time that coagulation activity is significantly increased 
in the left atrium of patients with mitral stenosis even during 
anticoagulation, which might contribute to the pathogenesis of 
thromboembolism in mitral stenosis. Our findings also suggest 
that platelet activity is not significantly increased in the left 
atrium of these patients. 
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